Summary & Overview
CPT 80326: Multi‑Amphetamine Toxicology Panel
CPT code 80326 represents a laboratory toxicology assay that detects or measures five or more amphetamines in a patient specimen. This code is used for multi-analyte amphetamine testing and is relevant across clinical settings where confirmation of amphetamine exposure or monitoring is required, including emergency departments, outpatient clinics, pain management programs, substance use treatment, and forensic or occupational testing contexts. Nationally, standardized coding for multi-amphetamine panels aids in consistent reporting, billing, and surveillance of stimulant use.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns and coding considerations for laboratory toxicology services using CPT code 80326.
Readers will find a concise overview of the clinical context for multi-amphetamine testing, the typical service setting, and the role of CPT code 80326 in claims. The report summarizes benchmarks and common billing modifiers where available, highlights implications for clinical workflows and lab operations, and flags areas where policy or coverage variability may affect reimbursement and utilization. Data not available in the input is explicitly noted where applicable.
Billing Code Overview
CPT code 80326 describes a laboratory assay in which a lab analyst measures the amount of or detects the presence of five or more amphetamines, a central nervous system stimulant, in a patient specimen. This service is a toxicology panel for multiple amphetamines used to identify or quantify amphetamine-class stimulants in biological samples.
Service Type: Laboratory — quantitative or qualitative toxicology testing
Typical Site of Service: Clinical laboratory or hospital laboratory
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient toxicology laboratory after a clinician orders confirmatory testing for suspected amphetamine exposure or misuse. Typical scenarios include: a behavioral health clinic monitoring adherence and abstinence in a patient prescribed amphetamine-based ADHD medication; an employer- or legal-directed confirmatory test following a positive urine drug screen; an emergency department evaluation of suspected overdose or altered mental status; or a pain-management program screening for non-prescribed stimulant use. The specimen (usually urine, occasionally serum or oral fluid) is received in the clinical laboratory. A laboratory analyst performs a definitive quantitative or qualitative assay capable of measuring or detecting five or more amphetamine analytes (for example amphetamine, methamphetamine, MDMA, MDA, MDEA) using techniques such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results are reviewed, validated by the laboratory director or supervising physician, and reported to the ordering clinician. The typical site of service is a clinical chemistry/toxicology laboratory, which may be located in a hospital outpatient lab, reference laboratory, or independent diagnostic testing facility (IDTF).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the physician or laboratory director professional interpretation/oversight separate from the technical testing. |